Xvivo Perfusion reported during the morning that Perfadex Plus has received a 510(k) market approval. Market launch has already been initiated in Europe and the company will now begin the launch in the USA in august. We have already accounted for the launch of the product in our model and today's news will therefore not result in any changes in our valuation of the company.